SGLT2 inhibitors increased the risk of urinary tract infection (UTI) in non-Asian patients with type 2 DM, but were associated with a similar risk of UTI as a placebo in Asian patients with type 2 DM7. Here, SLC5A2 is linked to urinary tract infection.